Chronic Prostate Inflammation May Increase Prostate Cancer Risk

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer, according to researchers.
Published Online: April 24, 2014

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer, according to researchers.

However, Dr. Elizabeth A. Platz told Reuters Health by email, "We don't anticipate direct clinical implications of our work. The prevalence of inflammation in the prostate was so high -- even in the controls (comparison men without a diagnosis of cancer) -- that the mere presence of inflammation could not be used as a tool to identify men at risk for this cancer."

"We performed the work to learn more about the etiology of prostate cancer, especially aggressive disease," added Dr. Platz, of Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

As reported April 18th online in Cancer Epidemiology Biomarkers & Prevention, Dr. Platz and colleagues conducted a case-control study nested in the placebo arm of a large cancer prevention trial. At enrollment, the men were at least 55 years old and had a normal digital rectal examination and a serum prostate-specific antigen (PSA) level of 3 ng/mL or less.

Read the complete stoy here: http://bit.ly/1mF25P9

Source: Medscape

 



Feature
Recommended Articles
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.
New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.
Physicians at the Brigham and Women’s Hospital have published results from a proof-of-concept study that used mass spectrometry in almost real-time to detect and delineate pituitary tumors from normal tissue.
Genevieve Kumapley, PharmD, BCOP, reflects on the significant out-of-pocket costs associated with oral oncolytics and suggests how a change in benefit design can help patients afford the treatments they need.